Trial intelligence / Profile preview

Engerix-B Junior with or without HBIG in newborns of HBeAg-positive mothers – 20-year follow-up

2011-004879-36Phase 4

Sponsor
GSK
Start
May 2015
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 4, randomised trial of hepatitis B vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Anti-HBs seropositivity rate, Anti-HBs seroprotection rate and 1 more.

02

Drugs

hepatitis B vaccine recombinant
03

Conditions

hepatitis B (HBV)

Beyond the preview

Go deeper on 2011-004879-36.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-004879-36.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call